Low Implanted Second Trimester Placenta and Placenta Previa


Placenta Previa is defined as a placenta implanted in the lower segment of the uterus, presenting ahead of the leading pole of the fetus (over or near the internal os). The prevalence of placenta previa has been estimated to be approximately 0.5% of all pregnancies, and this increase correlates to the elevated cesarean section rate . In Egypt, the prevalence of placenta previa is around 1.3% in Sohag Governorate and 1.5% in Aswan region according to. Although various studies have tried to address risk factors associated with Placenta Previa development, the etiology of placenta previa still remains obscure. Several risk actors have been identified as strong contributors to placenta previa development. It is also a significant contributor to severe postpartum hemorrhage.Risk factors include; history of previous cesarean section, advanced maternal age, history of previous abortions, high parity and substance abuse during pregnancy (cigarette smoking), placental size (multiple pregnancy), endometrial damage (previous dilatation and curettage), uterine scars and pathology (previous myomectomy or endometritis), placental pathology (marginal cord insertions and succenturiate lobes), previous placental Previa, and curiously.

Full Title of Study: “The Prediction of Risk Factors of Progression of Low Implanted Placenta at 18- 24 Weeks to Placenta Previa at Term”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 30, 2017


  • Radiation: ultrasound
    • to detect the placental site

Arms, Groups and Cohorts

  • Low implanted placenta group

Clinical Trial Outcome Measures

Primary Measures

  • The distance between lower edge of the placenta and internal os by ultrasound (millimeter)
    • Time Frame: 12 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. Pregnant women between 18-24 weeks. 2. Diagnosed to have low implanted placenta by ultrasound Exclusion Criteria:

1. Patient refused to follow-up in our setting. 2. Patient refused to perform Trans-vaginal ultrasound in the second trimester of gestation.

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Assiut University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mohammed Khairy Ali, Lecturer – Assiut University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.